As of July 10, 2026, influenza vaccines in France have been officially reclassified, moving them onto the “List I” of poisonous substances (substances vénéneuses). This regulatory shift mandates that all flu vaccines now require a medical prescription before they can be dispensed or administered, a change that impacts the operational protocols for physicians, pharmacists, nurses, and midwives across the country. The French National Agency for the Safety of Medicines and Health Products (ANSM) confirmed this update.
This transition marks a change from previous years, where the vaccination process was often streamlined. By categorizing these vaccines as List I substances, the health authorities have effectively tightened the procedural requirements for access, ensuring that a formal medical evaluation and a written order are now prerequisites for every patient seeking immunization.
Regulatory Reclassification and the Role of List I
The decision to classify flu vaccines under List I follows the standards set by the French Public Health Code. Substances listed under this category are considered to require more stringent control.
Under this new framework, while pharmacists, nurses, and midwives retain the legal authority to administer vaccines, they must now ensure that a valid prescription—issued by an authorized healthcare professional—is present.
Impact on Healthcare Professionals and Patient Access
For patients, the change means that the “walk-in” experience for influenza vaccinations may require an additional step: securing a prescription.
The Vidal medical database, a resource for French healthcare providers, has updated its monographs to reflect that the vaccine is no longer available for direct sale without a prescription.
Strengthening the Vaccination Chain
Please share your experiences or questions regarding these changes in the comments section below.
Worth a look